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ABSTRACT
Background: Myo-inositol (cis-1,2,3,5-trans-4,6-cyclohexanehexol; MI) is the most prominent of nine inositol stereoisomers. MI,
its phosphate derivatives, and associated lipids are widely found in vegetables and animal tissues and are known to participate in
numerous biological processes.
Objectives: To perform a review analysis on MI presence, functions, and impact in male fertility.
Materials and Methods: A thorough search of listed publications in PubMed on MI and its derivatives was done.
Results: Published information was found and compiled on MI identification, natural dietary sources and absorption, biosynthesis,
concentrations, as well as MI as its derivatives (PI, PIP, GPI, IPG) roles in several human tissues and body fluids in health and disease.
A section was focused on MI presence, biosynthesis, and functions in the mammalian male genital tract and in spermatozoa, and
summarized reports describing the impact of in vivo and in vitro MI supplementation on human semen quality and fertility. Studies
reported a discrete improvement in sperm motility in fresh and frozen-thawed semen, and a better sperm performance in natural
and assisted fertility.
Discussion and Conclusion: MI was reported as an effective supplement for sperm quality. In any case, several study designs lack
appropriate controls or data analysis to confirm the relevance of the findings. While promising, larger prospective randomized con-
trolled studies will be required to confirm the positive effect of MI supplementation in male infertility management. Moreover, fur-
ther investigations are encouraged to unravel MI roles in sperm physiology and the underlying molecular mechanisms.
INOSITOL SOURCES, BIOSYNTHESIS, AND ABSORPTION
Inositol is a sixfold alcohol (polyol) of cyclohexane, also called
cyclohexane-1,2,3,4,5,6-hexol, with five equatorial and one axial
hydroxyl (OH) groups. Its formula is C6H12O6 or (-CHOH-)6
(Fig. 1). Inositol exists in nine stereoisomers, resulting from
epimerization of the six OH- groups (cis-, epi-, allo-, myo-, neo-,
scyllo-, L-chiro-, D-chiro-, and muco-inositol; Murthy, 2006;
Thomas et al., 2016). The most prominent form widely occurring
in nature is cis-1,2,3,5-trans-4,6-cyclohexanehexol, or myo-inos-
itol (MI1) (former name ‘meso-inositol’), followed by D-chiro-
inositol (DCI) (Posternak, 1942; Fig. 1).
MI was first isolated in 1850 from Liebig’s meat extracts by J.J.
Scherer, who also determined its empirical formula (Scherer,
1850). Scherer named MI from the ancient Greek stem of ıς (is,
in-, ‘sinew, fiber’), -ose (indicating ‘a carbohydrate’), -ite
(‘ester’), and -ol (‘an alcohol’). In the following years, other
investigators further evaluated MI presence in animals and
plants, reported several methods to extract it, and evaluated its
importance in nature (Clo€etta, 1856; M€uller, 1857; Copper-Lane,
1861; Marme, 1864). Based on its empirical formula, these
reports related MI to sugars; in fact, it was named the ‘muscle-
sugar’, since muscle was one of its main sources. However,
Maquenne showed in 1887 that MI is not a sugar but a cyclic
hexamethylene compound, or hexahydroxyhydrobenzene; it also
established its cyclohexanol structure, and reported its purifica-
tion from leaves (Maquenne, 1887a,b,c). Around 30 years later,
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Needham described a procedure to quantify MI in animal tissues
and determined its levels in a set of rabbit tissues; moreover, it
showed identical characteristics between muscle MI and phytin
(Needham, 1923).
It has been established that MI, its phosphate derivatives, and
associated lipids are present in different food types (corns,
beans, fruits, nuts) and are widely distributed in several animal
tissues (Clements & Darnell, 1980; Schlemmer et al., 2009; Dini-
cola et al., 2017). MI is mainly present in animals in its free form
or as phosphatidylinositol (PI); in breast milk, is found in its free
form and as 6-b-galactinol (Naccarato & Wells, 1974). In vegeta-
bles, MI is found as phytic acid (inositol hexakisphosphate, inos-
itol-P6), which contains six phosphate groups partially ionized
at physiological pH (Holub, 1986). Phytic acid is the phosphorus
main form stored in many plant tissues, especially bran, seeds,
legumes, and oil, and has several functions with significant
nutritional roles (Dinicola et al., 2017). Western diets contain less
phytate because of massive refinement of grains and rice; for this
reason, MI diet contribution is approximately 1 g/day (Good-
hart, 1973). Despite the presence of plant food phytases, dietary
phytic acid is converted, after oral ingestion, to free MI,
orthophosphate, and intermediate forms (mono-, di-, tri-, tetra-,
and penta-phosphate esters of inositol) by bacterial phytases
and phosphatases during food processing in the large intestine.
These enzymes are homologous to mammalian inositol-P6
phosphatase (MINPP) and are responsible for dietary inositol-P6
digestion (Sandberg & Anderson, 1988; Schlemmer et al., 2001;
Schlemmer et al., 2009; Stentz et al., 2014). MI is absorbed by the
apical membrane of intestinal epithelial cells and reabsorbed in
the renal proximal tubes (Bissonnette et al., 2004). Several mole-
cules, such as glucose, modulate MI uptake (Haneda et al., 1990;
Cammarata et al., 1992); moreover, in vitro and in vivo results
support an increased MI intestinal absorption when combined
with alpha-lactalbumin administration (Monastra et al., 2018).
In addition to dietary ingestion, MI is synthesized by mam-
malian tissues, including brain, liver, kidney, mammary gland,
and testis. The ability of mammals to convert D-glucose to MI
was first reported in studies done in inositol-dependent (human:
KB and HeLa) and inositol-independent (mouse L-929) cell cul-
tures (Eagle et al., 1960). Later, it was found that brain, liver, and
kidney slices could convert glucose to MI (Hauser & Finelli,
1963). MI biosynthesis starts with glucose 6-phosphate, the first
glycolysis product, and comprises an isomerization reaction to
inositol-3-phosphate (Ins3P) by the inositol-3-phosphate syn-
thase (EC:5.5.1.4; IPS2). IPS requires NAD+ and involves a two-
step reaction of oxidation and reduction. Presently, the genomes
of over one hundred organisms, including humans, contain
annotated orthologs that encode IPS. Ins3P is then dephospho-
rylated into inositol by the inositol monophosphatase 1
(EC:3.1.3.25; IMP 1 or IMPase 1; Fig. 2). IPS is encoded by the
ISYNA1 gene and IMP 1 by the IMPA1 gene; their transcripts are
expressed in numerous tissues, as reported in a panel of the
Human Protein Atlas (Fig. 3A, 3B). In addition to IMPA1, another
IMPA transcript was first identified in humans, named IMPA2,
showing 54% amino acid identity to human IMPA1, and homol-
ogy to IMPAs of other organisms; it is located on chromosome
18p11.2, a region related to susceptibility for bipolar disorders
by linkage analysis (Yoshikawa et al., 1997). MI may be also
obtained by recycling inositol phosphates (Benjamin et al.,
2014).
Free MI plasma concentration in adult humans is 24.5 lM;
in contrast, millimolar levels are detected in other mammalian
tissues (Dawson & Freinkel, 1961; Hinton et al., 1980; Holub,
1986; Michaelis et al., 1993). MI is transported from the extra-
cellular fluid to the cell in a temperature-, pH-, and energy-
sensitive process (Schneider, 2015). There are three different
active cotransporters that use Na+ or H+ as co-solutes: SMIT1
(solute carrier family 5 member, third member of the solute
Figure 1 Inositol stereoisomers. Chair conformation of the nine stereoisomers of inositol: myo-, scyllo-, muco-, epi-, neo-, allo-, D-chiro-, L-chiro-, and cis-
inositol.
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carrier family3) is a high-affinity, Na+-dependent cotransporter
(Kwon et al., 1992; Matskevitch et al., 1998), SMIT2 is kineti-
cally similar but pharmacologically different (Coady et al.,
2002), and HMIT/SLC2A13 is the lower-affinity H+-dependent
transporter (Uldry et al., 2001). SMIT1 is an integral mem-
brane protein that transports 1 inositol with 2 Na+; it was the
first inositol transport system identified (Hager et al., 1995),
and it is encoded by the SLC5A3 gene (Kwon et al., 1992;
Fig. 3C). It structurally resembles glucose transporters, charac-
terized by inverted-repeat domains with many transmembrane
segments (Gamba, 2001; Abramson & Wright, 2009). In mam-
mals, both SMIT1 and SMIT2 react to osmotic imbalances
(Isaacks et al., 1994; Bissonnette et al., 2008; Klaus et al.,
2008), but no osmoregulatory functions have been found in
HMIT/SLC2A13. Mice deficient in SLC5A3 (SLC5A3/) have an
inositol uptake reduction of 96%, embryo developmental
abnormalities, and perinatal mortality, unless animals are fed
with MI from birth (Buccafusca et al., 2008). In line with these
findings, increased MI levels, reported in different tissues
under extracellular hypertonic conditions (Thurston et al.,
1989; Strange et al., 1991; Trachtman et al., 1991; Handler &
Kwon, 1996), have been attributed to increased Na+-dependent
transport activity (Strange et al., 1991; Handler & Kwon, 1996;
Matsuoka et al., 1999). Osmoregulatory elements have been
reported to control SLC5A3 gene transcriptional activity
(Trachtman et al., 1991; Handler & Kwon, 1996; Neuhofer
et al., 2002); specifically, expression of TonEBP (tonicity-re-
sponsive enhancer binding protein) transcription factor is
upregulated under hypertonic conditions, and it is translo-
cated to the cell nucleus.
MI biosynthesis may be subjected to positive and negative
modulators; among them, the glycogen synthase kinase 3 (GSK3)
is a positive regulator for optimal IPS activity, finding an inositol
decrease when GSK3 activity is lost (Azab et al., 2007). On the
other hand, gender and epigenetic modulation by tissue-specific
methylation (Seelan et al., 2011) may act as negative modulators,
as well as ISYNA1 alternative splicing, which leads to the expres-
sion of an isoform that impairs its activity (Seelan et al., 2009).
The amount of MI biosynthesized has been estimated in 4 g
(22 nmol)/day in the adult kidney (Clements & Diethelm, 1979),
far higher than dietary intake. It is found in large concentrations
in thyroid, testis, liver, brain, spleen, pituitary gland, and kidney.
Its excess is catabolically broken down in the kidney to yield O-
glucuronic acid and oxylulose-5-phosphate that enter the pen-
tose phosphate cycle, to finally be eliminated in the urine. In this
regard, renal failure has been associated with abnormalities in
MI metabolism and increased plasma levels (Pitk€anen, 1976). An
adequate MI supply is expected from biosynthesis and dietary
intake, but MI may be altered due to food processing,
biosynthesis impairment, absorption reduction, and excretion
increase, as summarized by Dr. Dinicola and collaborators
(Dinicola et al., 2017).
INOSITOL DERIVATIVES
MI is the precursor of biosynthesis of phospholipids (phos-
phatidylinositol, PI) and phosphatidylinositides (phosphatidyli-
nositol-phosphates, PIPs). In addition, it is involved in the
synthesis of water-soluble inositol phosphates (IPs) (Fig. 4).
Some PI is incorporated to PI glycan structures in the endoplas-
mic reticulum to form glycosylphosphatidylinositol (GPI)
anchors, tethering many proteins to the plasma membrane,
together with many other derivatives as inositol phosphoglycans
(IPG) and inositol ethers and esters (Livermore et al., 2016;
Fig. 4).
PI is biosynthesized de novo by an enzymatic reaction medi-
ated by the inositol phosphatidyl-transferase (PI synthetase, PIS)
(Michell, 2008); then, PI may be phosphorylated to form phos-
phatidylinositol-4-phosphate (PIP), phosphatidylinositol-
biphosphate (PIP2), and phosphatidylinositol-trisphosphate
(PIP3). These phosphorylated PI-based lipids, collectively known
as inositides or PIPs, are produced by a set of specific phospho-
inositide kinases (PIKs), including phosphatidylinositol-5-phos-
phate 4-kinase (PIP4K), phosphatidylinositol-4-phosphate 5-
kinase (PIPK1), and phosphatidylinositol-3-kinase (PI3K)
(Schoepp, 1985). Since steric hindrance has been considered to
hamper hydroxyl groups 2 and 6 to be phosphorylated, PIPs may
be found in seven different combinations resulting from phos-
phorylation of 3, 4, and 5 hydroxyl groups in the MI ring. How-
ever, there are reports suggesting the presence of a larger
molecular species array that differ by the acyl chain type
attached to the glycerol backbone (Leevers et al., 1999). Then, PI
(3,4,5)P3 acts as second messenger, by recruiting Akt serine–
threonine kinase (AKT) and PI-dependent kinase 1 (PDK1) to the
plasma membrane. AKT is activated to pAKT by mTORC2 phos-
phorylation (Traynor-Kaplan et al., 2017); the active form partici-
pates in a large and highly relevant number of cellular events.
Regarding inositol phosphate production, plants are able to
phosphorylate inositol by means of an inositol kinase that yields
IP3 (Ins-(3,4,5)-P3) (Sarbassov et al., 2005). In humans, inositol
phosphates are generated from phosphorylated forms by speci-
fic phosphatases, as well as from phosphoinositide hydrolysis
(Dietz & Albersheim, 1965). Phospholipase C (PLC) metabolizes
PIP2 (specifically PI-(4,5)-P2) into the intracellular second mes-
sengers 1,2-inositol 1,4,5-trisphosphate (IP3) and diacylglycerol
(DAG) (Thomas & Potter, 2014). In particular, binding of IP3
ligands to specific receptors (IP3R, type I-III isoforms) induces
Ca2+ release from the endoplasmic reticulum to the cytoplasm
(Nishizuka, 1986; Irvine, 1990). Then, Ins(1,4,5)P3 is rapidly
Figure 2 Inositol biosynthesis from D-glucose 6-phosphate. MI biosynthesis starts with isomerization of D-glucose 6-phosphate to 1D-myo-inositol 3-phos-
phate (Ins3P) by the inositol-3-phosphate synthase (IPS), which requires NAD + and involves a two-step oxidation/reduction reaction. The Ins3P is dephos-
phorylated by inositol monophosphatase (IMP 1) into myo-inositol (MI).
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Figure 3 IMPA1, ISYNA1, and SLC5A3 expression in human tissues. RNA expression analysis of IMPA1 (top), ISYNA1 (middle), and SLC5A3 (bottom) in a
large panel of human tissues (Data retrieved from Human Protein Atlas v18.1, https://www.proteinatlas.org/).
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metabolized to Ins(1,4)P2 and sequentially dephosphorylated to
render free MI. The number of inositol phosphates has grown
since the identification of the IP3/Ca2+ signaling mechanism
(Nishizuka, 1986).
Regarding GPI anchors, they were initially postulated in the
mid-1970s, while complete GPI structures were first described in
1988. GPI anchors associate with membrane lipid rafts, make
clusters, and transduce signals. Currently, numerous GPI-an-
chored proteins have been identified in eukaryotes, from proto-
zoa to humans, with diverse functions, such as coating proteins,
receptors, prions, adhesion molecules, and hydrolytic enzymes.
In mammals, GPI-anchored proteins can arise from alternative
splicing and have different functions (Albarran et al., 2016). Dif-
ferences in the GPI pathway of mammals and other eukaryotes
are the current focus in drug development against specific
pathogenic targets (Ferguson et al., 2017).
PATHOPHYSIOLOGY OF INOSITOL AND ITS
DERIVATIVES
In its free form, MI plays a highly relevant role as a cellular
osmolyte, protecting cells from environmental stress, by osmotic
compensation and consequent cell fluid and volume balance.
With other osmolytes, all called ‘chemical chaperones’, MI also
stabilizes and rescues misfolded proteins (Thurson et al., 1989;
Garcia-Perez & Burg, 1991; Gullans & Verbalis, 1993; Welch &
Brown, 1996; Yancey, 2005). In addition to these functions, MI
and its derivatives are involved in numerous biological pro-
cesses, including protein tethering to the cell surface, cell signal-
ing and vesicle trafficking, membrane excitability, regulation of
ion channel opening, intracellular calcium signaling, cytoskele-
ton and chromatin dynamics and remodeling, gene expression,
and epigenome regulation (Hammond et al., 2004; Roest et al.,
2017; Bevilacqua & Bizzarri, 2018; Ulicna et al., 2018; Bilanges
et al., 2019). Consequently, alterations in MI transport and meta-
bolism have been found associated with numerous pathological
conditions, including metabolic syndrome, type 2 diabetes and
gestational diabetes, thyroid dysfunctions, polycystic ovarian
syndrome and other gynecological disorders, abnormalities in
gamete production, fertilization and embryonic development,
Down’s syndrome, psychiatric disorders (i.e., depression, panic
disorders, obsessive compulsive disorder), Alzheimer’s disease,
preterm broncho-pulmonary diseases (including respiratory dis-
tress syndrome and retinopathy of prematurity), liver and
intestinal steatosis, and cancer. Several systematic analyses and
meta-analyses have extensively reviewed the impact of MI and
derivatives in health and disease (Berridge, 2016; Bizzarri et al.,
2016b; Chakraborty, 2018; Ramos et al., 2019).
Considering MI and its derivatives participation in numerous
biological processes and the association between abnormal
levels of these molecules and numerous pathologies, it has
already been established that an extra intake of MI as a dietary
supplement may be beneficial for several clinical conditions. MI
and inositol-P6 have been found to exert positive effects toward
several conditions, such as polycystic ovarian syndrome, gesta-
tional and type 2 diabetes mellitus, metabolic syndrome and
non-alcoholic fatty liver disease, pathologies related to excess
adiposity and hyperglycemia, insulin resistance, infant respira-
tory diseases, and cancer-related events (Vucenik & Shamsud-
din, 2006; Howlett et al., 2015; Bizzarri et al., 2016a; Lagana et al.,
2018; MacFarlane & Di Fiore, 2018; Michell, 2018; Owczarczyk-
Saczonek et al., 2018; Showell et al., 2018; Tabrizi et al., 2018;
Facchinetti et al., 2019; Vitagliano et al., 2019). Specifically
Figure 4 Inositol metabolism. Inositol is acquired by dietary ingestion of phytic acid, also known as inositol hexaphosphate (IP6). IP6 is metabolized into MI
by the multiple inositol-polyphosphate phosphatase 1 (MINPP1) and then transported into the cytosol through the sodium–myo-inositol cotransporter
(SMIT). Cytosolic glucose can also be used to synthesize MI through myo-inositol-phosphate synthase (MIPS). In the cytosol, MI can be metabolized into
phosphatidylinositol (PI) by phosphatidylinositol synthetase (PIS). PI and its derivates are concentrated in membrane pools. PI can be further phosphorylated
into phosphatidylinositol-(4)-monophosphate (PIP) by phosphatidylinositol-4-kinase (PIP4K), then into phosphatidylinositol (4,5)-biphosphate (PIP2) by
phosphatidylinositol 4-phosphate 5-kinase 1 (PIPK1), and finally into phosphatidylinositol (3,4,5)-triphosphate (PIP3) by phosphoinositide 3-kinase (PI3K).
Phospholipase C (PLC) metabolizes PIP2 into 1,2-diacylglycerol (DAG) and inositol (1,4,5)-triphosphate (IP3). In turn, DAG activates protein kinase C (PKC),
recruiting it to the plasma membrane. Similarly, PIP3 recruits and activates Protein kinase B (Akt). On the other hand, IP3 is phosphorylated by inositol
kinases (IPK) into inositol tetrakisphosphate (IP4), inositol pentakisphosphate (IP5), and inositol hexaphosphate (IP6) and dephosphorylated by inositol
phosphatases into inositol biphosphate (IP2) and inositol monophosphate (IP). Furthermore, IP3 activates IP3 receptor (IP3R), inducing calcium release from
the endoplasmic reticulum reservoir. IP can be used to synthesize glycosylphosphatidylinositol (GPI) anchors in the ER and transferred to the Golgi apparatus
(GA) to end up fusing to the plasma membrane.
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regarding polycystic ovarian syndrome, accumulating evidence
suggests that one of the most important mechanisms of its
pathogenesis is the insulin resistance; for this reason, the use of
insulin sensitizers, such as inositol isoforms, gained increasing
attention due to their effectiveness and safety profile (Monastra
et al., 2017; Lagana et al., 2017; Reyes-Mu~noz et al., 2018).
MI supplementation can be considered totally safe for humans
and, in particular, if 4 g dose/day is not exceeded. In this regard,
the effects of a MI overdose (4–30 g dose/day) have been evalu-
ated from 1 to 12 months in several trials, and only some mild
side effects in a small percentage of patients were reported (Biz-
zarri et al., 2016b). For all these reasons, several food supple-
ments containing MI in combination with several compounds,
including folic acid, melatonin, alpha-lactalbumin, glucoman-
nan, sorbitol, sucrose, maltodextrin, and vitamin D, were devel-
oped. However, it is important to pay attention to the possible
presence of mono-, di-, or polysaccharide excipients (i.e., mal-
todextrin, sucrose, and galactose) in these products, because
they may affect MI absorption due to competition for the same
transporters (Unfer, 2018). Other important aspects to consider
in a food supplement ‘therapy’ are the pharmaceutical form (i.e.,
powder, tablets, soft gels), the chemical characteristics of the
molecules used (i.e., pro-drug, salt form), the number and time
of administration, and the interference of other substances on
supplements absorption (i.e., caffeine, drugs). In this context, a
recent review work has gathered and analyzed information from
several scientific publications search engines (PubMed, Google
Scholar, and ResearchGate) on MI bioavailability, identifying
two studies that investigated the pharmacokinetic profile of MI
administration. This analysis revealed an advantageous protocol
of splitting a therapeutic dosage of 4 g MI into 2 g administra-
tions, twice a day, to be the best approach for one day coverage
(Orru et al., 2017).
MYO-INOSITOL AND DERIVATES IN THE MALE
REPRODUCTIVE TRACT
The detection of MI in male reproductive tract secretions was
first reported in the 1950s (Mann, 1951; Mann, 1954; Hartree,
1957). Specifically, Mann identified the boar seminal vesicles as
an exceptionally rich source of MI, with amounts around 2.4 g/
100 g fresh weight, much higher than those reported for most
plant and animal tissues (10–100 mg/100 g) (Mann, 1954). Using
a microbiological assay, Hartree determined MI levels in human
semen from 2 pools of at least 10 samples each, finding 50–
57.3 mg/100 g free MI and 53.6–62.8 mg/100 g total MI (Har-
tree, 1957). Results from Hartree’s study also highlighted the dif-
ference between MI concentrations in human seminal plasma
and blood, being ~100 times higher in the former (seminal
plasma free MI: 50 mg/100 mL; serum-free MI: 0.6 mg/100 mL).
In addition to free and total MI quantification in human seminal
plasma, Hartree’s study reported MI concentration in boar, bull,
rabbit, ram, and stallion seminal plasma, showing highest values
in boar [free MI (n = 3): 382-607 mg/100 g, total MI: (n = 2):
602, 725] and lowest in ram [free MI (4 pools of at least 10 sam-
ples each): 9.7–16.1, total MI (4 pools of 10 or more samples
each): 37.3–45.4] (Hartree, 1957). Later, other studies identified
free MI as a component of bull, guinea pig, monkey, rabbit, and
ram seminal fluid (Mann, 1964). Moreover, Nixon reported MI in
human semen from 20 patients classified as fertile, borderline,
and subfertile, finding an average of 64 mg/mL free MI in the
whole group (Nixon, 1964). In this report, no differences were
found between MI levels and patient fertility status [subfertile
(n = 4): 50–78 mg/100 mL; borderline (n = 4): 26–150; fertile
(n = 12): 32–104], although a small number of individuals were
evaluated in each group (Nixon, 1964).
In 1964, Eisenberg and Bolden described MI levels in rat testis
(range: 39–66 mg/100mg; n = 3), epididymis (206–222), seminal
vesicles (611–666), and seminal fluid (943, 1060; n = 2; Eisenberg
& Bolden, 1964). The seminal vesicles were pointed as the princi-
pal MI storage site in the male tract. The authors suggested a
possible role of MI in sperm maturation, based on the increased
levels found from testis to the epididymis, although no experi-
ments were reported to address the proposed role.
Other studies described high levels of MI in the male repro-
ductive tract (Hartree, 1957; Lewin & Beer, 1973; Voglmayr &
Amann, 1973; Ghafoorunissa, 1976; Pruneda et al., 2007). Lewin
& Beer’s study (Lewin & Beer, 1973) identified prostate secre-
tions as a major source of MI in human seminal fluid; in their
report, high MI levels were found in the early portion of split
ejaculates with elevated prostatic secretions, as judged by paral-
lel measurement of acid phosphatase (prostate biomarker) and
fructose (seminal vesicles biomarker). An extensive study by
Hinton and collaborators later described free MI concentration
in luminal fluid from rat, hamster, rabbit, rhesus monkey,
baboon, ram, and boar testis (seminiferous tubules and rete tes-
tis), epididymis (fractioned in proximal and distal caput and
cauda, mid, and distal corpus), and deferens duct (Hinton et al.,
1980). These authors reported the hamster as the species depict-
ing the highest MI concentration (distal cauda epididymis:
90 mM), followed by rat (deferens duct: 49.17 mM) and rhesus
monkey (proximal cauda: 17.40 mM). Taking into account the
fluid absorption process reported in the epididymis, mainly in
the testis proximal regions, the authors also estimated MI con-
centration in rat epididymis in the absence of absorption, show-
ing values up to 10 times higher when compared with observed
values (i.e., mid-corpus observed: 5.58 mM  0.46 versus esti-
mated: 40.31 mM). The authors proposed a possible role of MI in
sperm maturation, specifically on changes in the sperm mem-
brane and development of progressive motility and gamete stor-
age in the cauda epididymis. In line with these potential roles, a
low concentration of MI in the epididymis has been associated
with reduced fertility in a transgenic mouse model (Yeung et al.,
2004).
The presence of MI in the male gonad and other reproductive
organs could result from its uptake from blood. There are reports
showing a lower MI uptake by the testis or the epididymis, most
likely as result of the blood–testis and blood–epididymal barriers
blockage, suggesting active MI biosynthesis in the male gonad
and accessory organs (Middleton & Setchell, 1972; Lewin et al.,
1976; Waites & Gladwell, 1982). In particular, the report by Lewin
and collaborators described a study in which rats injected with
radiolabeled MI showed lower radioactivity incorporated to the
male reproductive tract organs than liver (% administered dose
testis: 0.47%  0.07; epididymis: 1.66%  0.23; vas deferens:
0.26%  0.02; seminal vesicle: 2.04%  0.48; prostate:
0.65%  0.38; liver: 14.90%  2.06; mean  SD), suggesting MI
production in the male gonad (Lewin et al., 1976). This report
also described a 12-fold blood serum concentration of MI in the
epididymis. MI transport in male reproductive tissues was later
confirmed by Hinton & Howards (Hinton & Howards, 1982),
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who described the highest transporting activity in the initial seg-
ment and early proximal caput rat epididymis and the lowest in
the testis and cauda epididymis. A low cauda transport activity
was also reported by Cooper (Cooper, 1982).
In addition to MI uptake, Eisenberg described an active sys-
tem to produce MI from glucose in rat testis, and identified the
seminiferous tubules as the most active component for MI
biosynthesis in the male gonad (Eisenberg, 1967). Later studies
showed ram testicular MI synthesized from blood glucose
(Voglmayr & White, 1971; Middleton & Setchell, 1972). In addi-
tion, other authors further characterized the presence and enzy-
matic activity of testis IPS and IMPA1 in rat (Robinson & Fritz,
1979) and bovine (Mauck et al., 1980) models. These enzymes
are subjected to a differential hormonal control, as revealed in
a study in which IPS activity decreased in the reproductive
organs and liver after hypophysectomy; on the other hand, ani-
mal thyroidectomy caused a similar decrease in the liver but
not in the reproductive organs (Hasegawa & Eisenberg, 1981).
While FSH and LH restored the activity to normal levels in the
testis, prostate, and seminal vesicles, it did not in the liver of
these animals.
Chauvin & Griswold (2004) were the first reporting transcript
expression of both enzymes involved in MI biosynthesis in
mouse testis. In addition, they evaluated the expression of
SLC5A3 cellular transporter. Expression of the three enzymes
was found in several tissues, including testis and epididymis.
Moreover, mRNA expression of the three enzymes was also
detected in Sertoli cells, while ISYNA1 and IMPA1 expression
was confirmed in round spermatids, and ISYNA1 mRNA in
pachytene spermatocytes. In addition, Sertoli cells subjected to
hypertonic conditions showed a significant increase in SLC5A3
and ISYNA1 mRNA levels, and an increased MI uptake. The
authors also confirmed previous observations from Robinson &
Fritz on the increase of MI production in Sertoli cells treated
with dibutyryl cAMP, revealing a regulation of SLC5A3 expres-
sion by FSH and dibutyryl cAMP (Robinson & Fritz, 1979). Con-
sidering MI osmoregulatory role in the kidney, and presence of
high MI levels in luminal fluid, the authors hypothesized on the
high production and secretion of the polyol by Sertoli cells,
pachytene spermatocytes, and round spermatids that are in con-
tact with the lumen. These cells also depict high expression of
ISYNA1 and IMPA1 genes; in this regard, the induction of their
expression under hypertonic conditions increased MI produc-
tion, as response to osmolarity changes. Also, SLC5A3 expression
in Sertoli cells and MI increased expression and uptake in hyper-
tonic conditions suggests MI as a key regulator of osmolarity in
the male gonad. Recent studies described regulation of ISYNA1
expression by p53 (Koguchi et al., 2016); furthermore, p53 was
reported to have a role in regulating mammalian spermatogene-
sis necrosis (Napoletano et al., 2017). The impact of these find-
ings on MI roles in spermatogenesis and sperm physiology has
yet not been described. Testis expression of the three enzymes
has been described in the Human Protein Atlas registries (HPA;
https://www.proteinatlas.org; large-scale analysis of the human
transcriptome; HG-U133A); the testis was the tissue with highest
expression (Fig. 5). Prostate and seminal vesicles’ mRNA expres-
sion of these enzymes was also reported in the HPA. These
records confirmed findings previously described in animals.
MI and its derivatives may be involved in endoplasmic reticu-
lum stress control in the testis (Gunes et al., 2015) and other
Figure 5 IMPA1, ISYNA1, and SLC5A3 expression in human testis RNA
expression analysis of IMPA1 (top), ISYNA1 (middle), and SLC5A3 (bottom
panel) in human testis, brain and kidney (Data retrieved from Human Pro-
tein Atlas v18.1, https://www.proteinatlas.org/).
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male reproductive tissues, that is, epididymis and prostate, as
reported in other tissues (Michell, 2008). In this regard, sper-
matogenesis is a highly complex proliferation and differentiation
process leading to sperm morphogenesis that involves extensive
protein synthesis, posttranslational processing, folding, and traf-
ficking to an appropriate cellular localization (Fawcett, 1975;
Neto et al., 2016). Moreover, it requires the identification and
destruction of both unfolded and misfolded proteins, by activat-
ing endoplasmic reticulum-associated proteasome-mediated
degradation, in which MI and derivatives play a key role (Guzel
et al., 2017). Several studies have focused on Sertoli cells, since
they have a key role in spermatogenesis by their close interaction
with germ cells and the active protein synthesis (Crisostomo
et al., 2018). Sertoli cells’ endoplasmic reticulum has been exten-
sively evaluated; a review work recently published by Vogl et al.
(2018) extensively describes the distribution of the endoplasmic
reticulum in testicular cells, the communication with the plasma
membrane and mitochondria, and its function. Once spermato-
zoa are released from the testis, they undergo maturation while
they transit the epididymis, acquiring progressive motility and
ability to recognize the oocyte (Sullivan & Mieusset, 2016). Fig-
ure 6 summarizes the MI site of production in the testis and epi-
didymis, as well as the sperm regions where MI and its
derivatives may act, impacting male gamete function(s).
At ejaculation, spermatozoa stored in the distal portion of the
epididymis mix with the accessory glands secretions and are
deposited in the female tract, where they undergo a set of com-
plex and coordinated changes to accomplish fertilization
(Satouh & Ikawa, 2018). Spermatozoa undergo capacitation, a
process by which they develop full fertilizing potential, as evi-
denced by their ability to undergo acrosome reaction and to
interact with the oocyte vestments (De Jonge, 2017; Puga Molina
et al., 2018). Several studies have identified MI phosphoderiva-
tives in sperm mechanisms related to these processes, including
progressive and hyperactive motility, sperm guidance, sperm
capacitation, acrosome reaction, and sperm–oocyte interactions.
With regard to sperm motility, it is well established that in the
oviduct, spermatozoa change the low-amplitude symmetrical
progressive tail movement for a more active high-amplitude and
asymmetric one, defined as hyperactive motility, to detach from
the oviductal epithelium and to penetrate the oocyte vestments
(Suarez, 2008). While signaling pathways responsible for hyper-
active motility have not been fully elucidated, evidence has been
shown on the involvement of a signal pathway in which PIP2 is
converted to PIP3 (Freitas et al., 2017); moreover, the involve-
ment of the PI3K–AKT pathway in sperm hyperactivated motility
was previously reported (Sagare-Patil et al., 2013). With regard to
sperm guidance, a thermotaxis mechanism has been described,
by which temperature stimulation activates PLC causing hydrol-
ysis of PIP2 to IP3 and DAG, and a consequent binding of IP3 to
its receptor in an internal Ca2+ store, triggering Ca2+ release,
altering sperm swimming directions (Bahat & Eisenbach, 2010).
In addition, spermatozoa that undergo capacitation depict
changes such as plasma membrane lipid rafts redistribution,
and actin cytoskeleton reorganization (Watanabe et al., 2017;
Breitbart & Finkelstein, 2018), processes in which MI derivatives
exert a relevant role. Regarding the former, the release of GPI-
anchored proteins from the lipid rafts has been proposed as a
crucial step for sperm fertilizing ability development (Watanabe
et al., 2017). It has been shown that a decrease in PIP2 synthesis
inhibits actin polymerization and sperm motility, whereas
increasing PIP2 synthesis enhances both activities; moreover,
the increase in filamentous actin during capacitation has been
related to the inactivation of the actin severing protein gelsolin,
by its binding to PIP2 (Breitbart & Finkelstein, 2018). Once sper-
matozoa are capacitated, they are capable to undergo the acro-
some reaction; in this regard, it has been proposed that PIP2,
DAG, and PA modulate IP3 production, which is crucial for this
process (Lopez et al., 2012).
IN VIVO MYO-INOSITOL SUPPLEMENTATION AND
IMPACT ONMALE FERTILITY
Based on current knowledge of MI presence and functions in
the male reproductive tract, the effect of in vivo MI supplemen-
tation in patients with seminal abnormalities, idiopathic infertil-
ity and metabolic syndrome, and in normozoospermic (N) men
has been evaluated in several studies. A summary of the publica-
tions in this topic is presented in Table 1: information on the
study type and design and number of subjects in the study, diag-
nostics, type of treatment, evaluated variables, results and statis-
tical differences, and citation.
Among them, a report of Calogero and co-workers described
the impact of MI oral treatment in a placebo-controlled study
done in men diagnosed with idiopathic infertility (Calogero
et al., 2015). The authors stated that patients in both groups
depicted similar values for all parameters evaluated, although a
statistical analysis between groups is not shown. In the MI-trea-
ted patients, lower levels of follicle stimulating hormone (FSH)
and luteinizing hormone (LH) levels were found, while increased
Figure 6 MI in the male genital tract and the spermatozoon. MI is produced
from glucose in Sertoli cells inside the testis seminiferous tubules. Addition-
ally, MI is acquired through blood supply in low levels due to the blood–tes-
tis barrier. Sperm cells can also acquire MI during epididymal transit.
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serum inhibin B levels and no changes in Prolactin and Testos-
terone (T) levels were reported. Regarding semen parameters,
sperm concentration, count, and progressive motility showed a
significant increase, although discrete, in MI-treated patients.
Results suggested a positive impact of MI treatment on men suf-
fering infertility. In this regard, inositol and its phosphoderiva-
tives are known to modulate FSH signaling in women (Lagana
et al., 2017), and in Sertoli cells as well (Casarini & Crepieux,
2019). This may represent an additional MI mechanism of action
which, by sensitizing Sertoli cells to FSH, might potentially
improve sperm parameters. As part of the study, the authors
reported an increase in spontaneous acrosome reaction in MI-
treated patients; while the authors speculated about the lack of
functional relevance of this parameter, they did not discuss
these unexpected high scores found in all groups, and the unde-
sired increase found in the MI-treated patients. The values
reported in samples from both groups assessed prior to treat-
ment, as well as after treatment in placebo groups are similar
(34%, 35%, and 36%, respectively) and much higher than those
reported in the literature (i.e., Byrd & Wolf, 1986). Since the
method used to assess the acrosome status is a standard proce-
dure, it would not cause these high acrosome reaction values;
whether the significant increase in the acrosome reacted sper-
matozoa in the MI-treated patients is the result of changes in
phospholipids concentrations of the sperm membrane is not
evaluated or discussed. These findings should warrant further
investigations to assess the impact of MI on sperm membrane
stability.
In the same year, Gulino and collaborators published a study
designed to assess the effect of MI treatment in individuals dis-
tributed in three groups: one composed of healthy fertile (HF)
men, another composed of oligoasthenozoospermic (OA) men,
and a control group of healthy patients treated because of a
female factor (Gulino et al., 2016). This last group was not always
included in the analysis, leaving open the question of their inclu-
sion in the study design. The authors described the use of two
well-established procedures to select the motile sperm fraction,
swim-up and density–gradient centrifugation used in the IVF-
ICSI treatment procedures. The swim-up method was done from
the sperm pellet, a procedure that is widely discouraged because
of reactive oxygen species (ROS) release from dead and damaged
spermatozoa; however, results presented only referred to the
density-centrifugation method. One very important point in this
study is the lack of a placebo group, considering that MI formu-
lation provided to the patients also contains folic acid. Although
the authors described the results of each group, data are pre-
sented in a peculiar way for each reported parameter (semen
volume, sperm count before and after sperm selection, and pro-
gressive motility). The authors refer to count, while reporting
sperm concentration, as judged by the units (million/mL). An
increase in sperm concentration but not in sperm motility is
reported in both groups after treatment, and results are pre-
sented in a very confusing manner. Moreover, the authors report
an increase in sperm concentration after sperm selection in both
groups, although again data analysis is rather unconvincing.
In 2016, Montanino Oliva and co-workers studied a group of
asthenozoospermic (A) patients diagnosed with metabolic
syndrome, and evaluated sperm parameters before and after
treatment with a commercial supplement containing MI
(Montanino Oliva et al., 2016a). Several parameters established
by the National Cholesterol Education program were used to
assess whether patients were affected with metabolic syndrome.
Although no changes were found in body mass index (BMI),
waist circumference (WC) and levels of Triglycerides, the home-
ostatic model assessment for insulin resistance (HOMA) index
was decreased after MI supplementation. These changes were
accompanied by a decrease in Estradiol (E2) and sex hormone-
binding globulin (SHBG) levels; moreover, LH and free/total T
levels were found increased in MI-treated men (Michalakis et al.,
2013). After treatment, sperm concentration, motility and mor-
phology depicted a significant discrete increase, estimated in
approximately 20%. No information was shown on the propor-
tion of samples that reached normal values, or any sperm func-
tional tests in treated men. While results appeared promising,
they may not be totally attributed to the MI, since the commer-
cial formulation also contains L-carnitine, L-arginine, vitamin E,
selenium, and folic acid, and a placebo control group was not
included in the study design, essential to confirm the relevance
of the reported findings.
One year later, Dinkova and collaborators described the
impact of MI treatment on semen parameters in a prospective
longitudinal study done on A patients (Dinkova et al., 2017). The
authors indicated that semen parameters were evaluated in all
patients prior and after treatment, but results of average sperm
motility were only presented, and no indication of whether it
was total or progressive motility was given. In response to MI
treatment, the authors reported a significant increase in the per-
centage of motile spermatozoa, reaching normozoospermia in
34.9% of the cases, and no response in 12.8% of the cases. How-
ever, no information was provided on the total motile count, to
determine the impact of MI treatment on sperm production and
quality, information that was available since the authors indicate
they evaluated all semen parameters. In the conclusion, the
authors highlighted the safety of MI, and propose its use to man-
age idiopathic infertility, but the study does not address the
impact of this compound in patients with unexplained infertility,
but in men with alterations in sperm motility.
In the same year, a report by Capece and collaborators
described a study done to assess the impact of MI patient treat-
ment on routine semen parameters and DNA fragmentation
(Capece et al., 2017). MI was administered as a complex with
other components to a group of patients with semen abnormali-
ties. Although patient group was defined as oligoasthenoterato-
zoospermic (OAT), they were A, oligoteratozoospermic (OT),
asthenoteratozoospermic (AT), and OAT. In addition to a hor-
mone panel, semen analysis (WHO manual 2010) and DNA frag-
mentation (TUNEL) were evaluated (no cut off values of
normality for TUNEL were indicated); after randomization both
groups had comparable baseline values for all parameters.
Results were presented as the difference between baseline and
follow-up, displaying data in a complex way, making difficult the
assessment of changes caused by the treatment. The authors
claimed a significant overall increase in sperm concentration and
progressive motility, and a decrease in DNA fragmentation, while
no changes were reported in sperm vitality, total motility, normal
morphology, as well as LH, FSH and T levels between treated and
control patients. No other data was presented; in particular,
results on A men (largest subgroup) in whom the impact of MI
treatment on all parameters studies would have been important
to report if contrasted with a specific placebo group.
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Table 1 In vivo supplementation with MI and impact on male fertility









2 g MI + 200 µg folic
acid (n = 98)
Group 2 (placebo):
200 µg folic acid
(n = 96)
Twice a day for
3 months
(mean  SD; p < 0.05)
(Comparison post-MI vs post-placebo)
FSH (IU/L):
Post = 10.7  4.1, Pre = 16.7  4.1
LH (IU/L):
Post = 8.8  2.6, Pre = 12.1  2.6
Serum inhibin B (ng/L):
Post = 105.0  28.0,
Pre = 86.0  24.0
Sperm concentration (million/mL):
Post = 26.4  4.4, Pre = 20.2  4.6
Sperm count (million):
Post = 57.6  14.4,
Pre = 46.6  12.6
Progressive motility (%):
Post = 27.6  1.8, Pre = 22.2  2.1
Acrosome reaction (%):
Post = 41  11, Pre = 34  8




Prospective study 62 13 OA




4 g MI + 400 µg folic
acid





Post = 10.06, Pre = 6.38;
Change: +126.89% (p < 0.01).
HF (N)
Sperm concentration (million








Post = 4.15 million spermatozoa/mL,
Pre = 1.63; Change: +306.56
(p < 0.001)
HF:
Post = 44.31 million spermatozoa/mL,
Pre = 21.59, Change: +132.02
(p < 0.01)
Sperm motility not improved in either
group.
Observations:
-No placebo group was included for
the OA and HF patients.
-Data presented did not include
standard deviation of the mean
despite describing results of a patient
group.
Significant differences were not clear.
Gulino et al. (2016)
Prospective
longitudinal





1g MI + 30mg L-
carnitine, L-arginine,
vitamin E + 55 µg
selenium + 200 µg
folic acid




Post = 27.0  3.1, Pre = 28.1  3.5
(NS)
WC (cm)
Post = 105.3  3.3,
Pre = 107.1  4.2 (NS)
Triglycerides (mg/dL)
Post = 173.2  13.4,
Pre = 175.4  12.5 (NS)
HOMA (index):
Post = 1.6  0.7, Pre = 2.8  1.2
(p < 0.001)
E2 (pg/mL):
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Table 1 (continued)
Type N Diagnostics Treatment Results Refs
Post = 35.8  3.5, Pre = 55.0  4.9
(p < 0.001)
LH (mIU/mL):
Post = 3.3  1.2, Pre = 2.5  1.3
(p < 0.01)
Free T (pg/mL)
Post = 47.2  13.0,
Pre = 33.0  11.1 (p < 0.001)
Total T (ng/mL):
Post = 3.7  1.4, Pre = 2.8  1.2
(p < 0.02)
Sperm concentration (million/mL):
Post = 20  4.2, Pre = 16.2  3.4
(p < 0.001)
Sperm motility (%):
Post = 51.4  7.2, Pre = 39.6  6.1
(p < 0.001)
Normal sperm morphology (%):
Post = 30.1  2.3, Pre = 24.9  2.0
(p < 0.001).
Observations:




109 A Andrositol (MLD
Trading, Bulgaria)





200 lg of folic acid




Post = 27.98%  9.69,
Pre = 20.31  8.5 (p < 0.05)
Restauration to normozoospermia:
34.9% (38/109)
No changes: 12.8% (14/109)
Worsening: 1.84% (2/109)
Observations:
It is not indicated whether changes


















1 g MI, 300 mg
Tribulus Terrestris,
200 mg Ecklonia
Bicyclis Alga and Bovis





MI-treated = 3.82, placebo-
treated = 1.71 (p = 0.048)
Progressive sperm motility
Average increase:






0.39 (p = 0.001)
Observations:
Results were presented as a difference
between baseline and follow-up.
No actual values of variables in MI-













1 g MI, 800 mg alpha-
lipoic acid, 400 mg
folic acid, 100 mg
betaine, 1.7 mg
vitamin B2, 1.9 mg
vitamin B6, 2.62 mg
vitamin B12.




Post = 24.4 million/mL  23.4,
Pre = 16.6  13.1,
Change=+41.2% (p = 0.0009)
Sperm count:
Post = 69.1 million
spermatozoa  59.0,
Pre = 46.5  38.7, change = +50%
(p = 0.0017)
Progressive motility:
Post = 24.8%  16.5,
Pre = 19.5  15.6,
Change = +31.6% (p = 0.0047)




© 2019 American Society of Andrology and European Academy of Andrology Andrology, 1–22 11
MYO-INOSITOL: OVERVIEW & IMPACT ONMALE FERTILITY ANDROLOGY
Regarding the impact of MI on DNA fragmentation, phospho-
inositide lipids (PPI) are found 10 times more enriched in the
nucleus, where they regulate transcription, RNA splicing and
DNA damage response. Wang et al. (2017) found an increase in
intranuclear PPI levels within 1 sec of laser microirradiation.
Moreover, PPI presence is essential for Ataxia telangiectasia and
Rad3-related protein (ATR)-mediated DNA damage response.
This is highly relevant, since double-strand breaks damage
response is primarily led by ATR/ATM kinases (Larsen & Stucki,
2016), being this a ROS-mediated injury in sperm germ cells that
may lead to translocations and cell death (Gunes et al., 2015).
In a recent report, Canepa and co-workers described a treat-
ment with a commercial formulation containing MI, in individu-
als depicting one or more altered semen parameters (Canepa
et al., 2018). While patient treatment resulted in an increased
sperm concentration and count, progressive motility, total
motile sperm count, and normal sperm morphology, no placebo
group was included in the study design. This was highly relevant,
considering that treatment was done with a complex containing
MI, alanine, betaine, folic acid and vitamins B2, B6, and B12.
The authors also reported a reproductive follow-up of patients
from the study group, indicating that 40% pregnancies were
achieved, either spontaneously or after ART procedures up to
6 months after treatment; however, no control placebo group
was reported to compare this outcome and confirmed its associ-
ation with the treatment.
Another study that evaluated the reproductive outcome
after MI patient treatment comes from a report by Montanino
Oliva et al. (2016b) on sperm performance done in women
treated with MI vaginal suppositories. Briefly, this case–con-
trol open-label study used two-phase strategies and lasted
two menstrual cycles. Ovulation was monitored in both cycles
after which a post-coital test was done. In the second cycle,
patients used a MI vaginal suppository for three consecutive
days, starting when the leading follicle was over 16 mm. As
result, no differences were found when the semen samples
from the pre- and post-partner treatment were evaluated on
day 9 of the menstrual cycle. However, a significant improve-
ment was observed in the post-coital test semen parameters
from women treated with MI, finding an increase in total and
progressive sperm motility, and a concomitant decrease in
the percentage of immotile spermatozoa. Although promising,
no placebo control was included in the study design and no
other reports from this group or others replicated these
findings.
IN VITRO SEMEN SUPPLEMENTATION WITH MYO-
INOSITOL AND IMPACT ON SPERM FERTILIZING
POTENTIAL
In addition to the effect of in vivo supplementation, the
impact of MI was further evaluated in a set of in vitro studies
Table 1 (continued)
Type N Diagnostics Treatment Results Refs
Post = 22.3 million
spermatozoa  30.8,
Pre = 9.8  11.5,
Change=+120% (p = 0.0010)
Normal sperm forms:
Post = 7.9 %  4.1, Pre = 4.9  3.1,
Change=+60% (p < 0.0001)
Follow-up 6 months: 40%
pregnancies spontaneously (6%) or
after ART procedures (4 IUI, and 30
FIV-ET or ICSI).
Observations:
No placebo group was included.
Case–control open-
label study












In the second cycle,






The post-coital test was
repeated after
treatment.
No differences found in semen
samples from Pre- and post-partner
treatment, evaluated on day 9 of the
menstrual cycle.




Post = 50.8 %  11.1,
Pre = 40.8  20.4
(p < 0.05)
Progressive sperm motility:
Post = 29.0 %  7.5,
Pre = 15.8  10.6
(p < 0.001)
% Immotile spermatozoa:
Post = 49.2 %  10.5,
Pre = 59.2  20.4
(p < 0.05)
Observations:
No placebo group is included.
Montanino Oliva
et al. (2016b)
A, asthenozoospermic men; O, oligozoospermic men; OA, oligoasthenozoospermic men; OT, oligoteratozoospermic men; OAT, oligoasthenoteratozoospermic men;
N, healthy fertile men. Text in light blue highlights outcome for fertility treatment.
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using semen samples depicting normal and abnormal sperm
parameters. A summary of the reports is shown in Table 2, fol-
lowing a structure similar to that described for Table 1.
Firstly, a report by Calogero’s group described the impact of
in vitro MI supplementation on sperm mitochondrial membrane
potential in semen samples from N and OAT patients (Con-
dorelli et al., 2011). After liquefaction, semen samples were sup-
plemented with MI or placebo, resulting in increased
percentages of spermatozoa depicting high mitochondrial
potential, and reduced percentages of spermatozoa with low
mitochondrial membrane potential in OAT patient samples.
Contrasting with these findings, no significant changes in mito-
chondrial potential were found in N semen samples after MI
supplementation. Moreover, MI supplementation of semen
samples from N and OAT men resulted in higher, although not
significant, percentages of spermatozoa depicting Phosphatidyl
Serine (PS) externalization as a signal of apoptosis. Moreover, a
trend toward a decrease in abnormal chromatin compactness
was also observed in spermatozoa from semen samples incu-
bated with MI, although differences again did not reach statisti-
cal significance. Assessment of a larger number of subjects could
have helped confirming or disregarding these findings that may
impact in other sperm fertility-related functions. Following these
findings, one year later the same group reported the results of
semen supplementation with MI followed by swim-up sperm
selection in a cohort of N and OA patients (Condorelli et al.,
2012). In this study, the authors reported enhanced progressive
cell motility and mitochondrial membrane potential of sperma-
tozoa from OA men after MI treatment prior to the sperm swim-
up selection. Furthermore, post-swim-up sperm motility (total
and progressive) and sperm count were reported significantly
increased in both N and OA patient MI-treated samples. The
authors include in the report a figure with results on total and
motile sperm motility, although values differ from those listed in
the table. Moreover, authors report no significant changes in PS
externalization and chromatin compactness. In a review pub-
lished in 2017, Condorelli and collaborators proposed some bio-
logical MI roles, as potential prokinetic, antioxidant and
hormonal modulator. In addition, they summarized prior find-
ings from their group and others about the impact of MI on
sperm quality, and propose an algorithm to identify astheno-
zoospermic patients that may benefit from its supplementation,
which includes the assessment of MMP (Condorelli et al., 2017).
To further assess MI benefits, Scarselli et al. (2016) described
its effect on semen samples depicting hyper viscosity. Specifi-
cally, this study enrolled patients without testicular pathology
but abnormal high semen viscosity. As working protocol, semi-
nal plasma was removed by centrifugation, spermatozoa were
resuspended in a commercial MOPS-buffered medium (G-
MOPSTM PLUS) and separated in two aliquots, one of which was
supplemented with MI; this treatment resulted in increased
sperm motility when compared to the control, suggesting a posi-
tive effect of MI on sperm motility in sperm suspensions devoid
of seminal plasma proteins. When samples were classified
according to the response in High (≥60–100%)-, Medium (≥30–
<60%)-, Poor (≥1–<30%)-, and No (0%)-responders, hyperviscous
semen samples were found to respond in over 90% of the cases,
being 57.6% defined as High-responders and 24.2% as Medium-
responders. They also evaluated the effect of the same short
incubation with MI on samples from patients with grade II and
III varicocele. In these cases, although the overall percentage of
motile spermatozoa was similar in treated and control samples,
a response was found in over 60% of the samples following crite-
ria defined above.
In the same year, Palmieri et al. (2016) described the
impact of in vitro sperm treatment with MI on total and pro-
gressive motility in fresh semen samples from N, O, A and
OA subjects. Samples supplemented with MI and incubated
for a short time at 37 °C showed an improvement in total
and progressive sperm motility compared to controls. As indi-
cated by the authors, a higher progressive than total motility
was unexpected, since semen analysis was done following
2010 WHO guidelines. Semen samples were also subjected to
swim-up or discontinuous density-gradient sperm selection
procedures in the presence or absence of MI; in this section,
the authors presented these findings as a sperm capacitation
rather than a sperm selection procedure. A decrease in sperm
total motility after selection with MI was found; in addition,
similar values for sperm progressive motility were reported
regardless of treatment. A similar evaluation done using pen-
toxifylline also did not improve sperm motility. In the same
report, the authors evaluate the effect of MI supplementation
on frozen-thawed semen samples. In their study, incubation
with MI resulted in an overall significant although discrete
improvement in progressive sperm motility, depicting a large
variance among samples.
In 2017, Artini et al. (2017) reported results on MI in vitro sup-
plementation in a cohort of N and OAT patients using a com-
mercial product. A short treatment resulted in a discrete
increase in progressive motility of both N and OA patient’s
semen samples, compared to control samples incubated in stan-
dard medium. Furthermore, total sperm motility was also
improved in N patient samples treated with MI, an effect that
was not found in the Condorelli’s study.
The impact of in vitro semen supplementation with MI on
DNA fragmentation was addressed in a cross-sectional study
presented at the 2015 ESHRE meeting by Parmegiani et al.
(2015). Although a preliminary report, a significant overall
decrease in DNA fragmentation was determined in MI-treated
spermatozoa.
Another 2015 ESHRE meeting report by Paternostro and
collaborators evaluated MI impact on sperm cryopreservation
(Paternostro et al., 2015). Semen samples were assessed
according 2010 WHO criteria and cryopreserved using slow
freezing with medium supplemented with or without MI.
Comparing with the control aliquot, an improvement of
sperm motility was observed in 50% of the cases. An average
reduction in DNA fragmentation after thawing samples sup-
plemented with MI was found in a large proportion of the
samples. This was a promising study, considering the well-
known negative impact of sperm cryopreservation on sperm
motility and DNA damage. No details on the response to cry-
opreservation with MI in relation to the initial semen parame-
ters were presented.
In 2018, Saleh and collaborators reported a randomized con-
trolled cryopreservation trial in a group of infertile men, supple-
menting semen cryoprotectant with MI (Saleh et al., 2018). After
thawing, total and progressive motility and the progressive cryo-
survival rate (CSR = post-thaw progressive motility/pre-freeze
progressive motility x100) were higher in samples supplemented
© 2019 American Society of Andrology and European Academy of Andrology Andrology, 1–22 13
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Table 2 In vitro supplementation with MI and impact in male fertility
Type N Diagnostics Treatment Outcome Refs
Prospective study 17 5 N
12 OAT
Semen supplemented with 2 mg/
mL MI and incubated for 2 h
MMP (flow cytometry following JC-1
staining)
Showed improvement in MMP only in OAT
patients (p < 0.05).
MI supplementation did not induce
changes neither in % spermatozoa with





With MI = 7.9  4.1; Without
MI = 2.7  1.1 (NS)
OAT
With MI = 8  2.5; Without




With MI = 17.5  3.1; Without
MI = 19.  3.6 (NS)
OAT
With MI = 23.7  2.9; Without
MI = 27.3  2.9 (NS)
Condorelli et al.
(2011)
Prospective study 40 20 N
20 OAT
Semen supplemented with 2 mg/
mL MI and incubated for 2 h,
followed by swim-up for 30 min.
OAT
(mean  SEM)
Progressive sperm motility (%):
Post = 42  4.0; Pre = 28.0  4.0
(p < 0.05).
MMP
% spermatozoa with high MMP:
Post = 80.0%  2.0; Pre = 58.0  4.0
(p < 0.05)
% spermatozoa with low MMP:
Post = 15%  3.0; Pre = 38.0  4.0
(p < 0.05).
Sperm vitality and chromatin compactness
were similar in sperm suspensions from
MI-treated and placebo control samples.
Post-swim-up sperm motility (% total and
progressive) and sperm count were





Prospective study 33 Patients without testicular
pathology but abnormal
high semen viscosity
(semen threads of >2 cm
length)
Semen centrifuged at 1800 rpm/
10 min, resuspended, and
incubated with 2mg/mL MI
(Andrositol DGN, Lo.Li.
Pharma, Rome, Italy: 133 mg/mL
MI in 9 mg/mL sodium chloride)
for 15 min at 37 °C
(mean  SD)
Sperm motility (%):
MI-treated = 38.9%  3.0;
control = 24.35  2.41 (p < 0.0001)
Samples classified according to
Andrositol DGN criteria: High (≥60–
100%)-, Medium (≥30–<60%)-, Poor (≥1
–<30%)-, and No (0%)-responders.








Prospective study 30 Patients diagnosed with
grade II and III
varicocoele.
Semen centrifuged at 1800 rpm/
10 min, resuspended, and
incubated with 2 mg/mL MI
(Andrositol DGN, Lo.Li.
Pharma, Rome, Italy: 133 mg/mL
MI in 9 mg/mL sodium chloride)
for 15 min at 37 °C






Overall % motile spermatozoa was




Prospective study 100 46 N
19 O
15 A
Semen supplemented with 15 µL/
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Table 2 (continued)
Type N Diagnostics Treatment Outcome Refs
20 OA Pharma, Rome, Italy) and
incubated 15 min at 37 °C




MI = 56.91  20.68,
control = 47.76  20.64
(p ≤ 0.05)
Swim-up or discontinuous density-gradient
sperm selection procedures in the
presence or absence of MI.
Total sperm motility (%):
MI = 70.87  31.46,
control = 73.99  28.94
(p ≤ 0.05)
Progressive motility (%):
MI = 70.67%  26.72,
control = 69.97  27.27). (ns).
A similar evaluation with pentoxifylline did
not improve sperm motility




(Sample from biopsy or fresh
ejaculate;
volume of less than 1.5 mL)
Frozen-thawed sample
supplemented with 3,2 mg/mL MI
and incubated 15 min at 37 °C
Total sperm motility (%):
MI = 14.88%  16.86,
control = 11.4  16.51 (ns)
Progressive motility (%):
MI = 16.4  20.64, control = 9.8  14.1
(p < 0.05)




Prospective study 63 31 N
32 OA
Semen supplemented with 2 mg/
mL MI (Andrositol-LAB, Lo.Li.
Pharma, Rome, Italy) and
incubated 30 min at 37 °C
(mean  SD)
Total motile sperm concentration:
N
MI-treated = 50.2  20.9 million/mL,
control = 44.6  21.2 (p < 0.05)
Progressive motile sperm concentration:
N
MI-treated = 36.6  28.9 million/mL,
control = 31.8  28.5 (p < 0.05)
OAT
MI-treated = 6.6  6.2 million/mL,
control = 4.5  2.1 (p < 0.05).
Observations:
No significant changes in Total motile
sperm concentration in OAT patients
Artini et al. (2017)
Cross-sectional study 10 Men attending infertility
clinic.
Sample divided into four aliquots,
1 left in seminal plasma (SP-4h), 1
in SP + 2 mg/mL MI (Andrositol-
LAB; Lo.Li. Pharma; Rome, Italy)
(SP-4h + MI), one in SP + 1:2
medium (SP-4h + culture
medium), 1 diluted as
before + MI SP-4h + culture
medium + MI).
All aliquots incubated for 4 h
DNA fragmentation (sperm chromatin
dispersion method; %)
(500 spermatozoa/sample).
baseline: 24% (1200/5000 spermatozoa),
SP-4h: 51.6% (2580/5000),
SP-4h + MI: 40.9% (2045/5000),
SP-4h + culture medium: 35.8% (1790/
5000),
(p < 0.001 all between aliquots and
baseline)
SP-4h + culture medium + MI=24.5%




Prospective study 90 Men subjected to basic
semen analysis
Semen cryopreserved (slow freezing)
with freezing medium





Reduction (3.7%) = 66/90
Increase (2%) = 9/90
No variation (16%) = 15/90








(9 excluded; final 41)
Evaluated as total (n = 41)
(only shown) or normal
(n = 15) and abnormal
(n = 26)
Semen samples supplemented with





Pre-freeze = 50 (30–50)
Post-MI: 15 (10–35)
Post-control = 10 (6–30)
(p = 0.15, post-MI vs post-control)
Saleh et al. (2018)
(continued)
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with MI prior to cryopreservation. A preliminary report had been
presented at ASRM 2017 (Saleh et al., 2017).
Recently, Mohammadi et al. (2019) reported the results on
semen supplementation with MI prior to cryopreservation in
semen samples from N young men without pathologies
related to semen abnormalities (i.e., varicocoele, accessory
gland infection, cigarette smoking, among others). Cryopre-
served samples were thawed after one month and analyzed.
As result, a significant improvement was observed in total
and progressive motile spermatozoa, as well as normal sperm
Table 2 (continued)
Type N Diagnostics Treatment Outcome Refs
Progressive motility (%):
Pre-freeze = 35 (20-35)
Post-MI: 10 (5-20)
Post-control = 5 (3-15)
(p = 0.14, post-MI vs post-control)
Cryo-Survival Rate (%):
Post-MI = 40 (25–70)
Post-control = 30 (13–58)
(p = 0.041, post-MI vs post-control)
Prospective study 40 N Semen divided into two aliquots ad
cryopreserved: one with 2 mg/mL
MI; one without MI (control), slow
freezing cryo.
(mean  SE)
Total sperm motility (%) (CASA):
MI = 19.62  2.68,
control = 16.32  2.75 (p = 0.045).
Progressive sperm motility (%) (CASA):
MI = 16.97%  1.86, control:
12.77  1.78). (p = 0.042).
Normal sperm morphology (%) (CASA):
MI = 11.9  0.97, control = 9.57  0.9
(p = 0.019).
ROS (reactive oxygen species)
(ns; MI vs control)
TAC (total antioxidant assay)
(p < 0.001 MI increased compared to
control).
MDA (malondialdehyde)
(p < 0.05 MI decreased compared to
control)
DNA fragmentation (TUNEL)




Prospective study 30 Semen preparation media with
2 mg/mL Andrositol-LAB
(Lo.Li Pharma, Rome, Italy).
IUI
Clinical pregnancy:
MI = 33.3%, control = 20.4% (p: 0.0492).
Note: MI-treated couples compared to a
control group (retrospective) of 28 cases




Prospective study 376 Group MI: (n = 144)
Group control (n = 232)






spermatozoa washed twice in the
MI presence or absence
Pregnancy rate:
A + MI=28.8%, A-MI = 18.8;
OA + MI=33.3%, A-MI = 25.0% (ns)
Note: Sperm parameter values were similar
in cell suspensions incubated with or
without MI
Park et al. (2016)
Prospective bicentric
randomized study
78 Group MI (n = 262
oocytes)
Group placebo (n = 238
oocytes)
Semen supplemented with 2mg/
mL Andrositol-LAB (Lo.Li
Pharma, Rome, Italy) or placebo
for 20 min.
Washed and subjected to swim-up
with MI or placebo-
supplemented medium for 30-
60 min
Spermatozoa recovered used for
ICSI
(mean  SD)
Motile spermatozoa in swim-up selected
(%): MI = 72.9  24.3,
placebo = 67.8  24.2 (p = 0.004)
Fertilization rate (%):
MI = 78.9  28.6, placebo: 63.2  36.7
(p = 0.002)
Day 3, grade A embryos (%):
MI = 59.8  35.6,
placebo = 43.5%  41.5 (p = 0.019)
Expanded blastocysts (%):




MI = 21.3, placebo: 13.6% (ns)
Pregnancy rate (%):
MI = 35.1, placebo = 20.0 (ns)
Rubino et al.
(2015)
A, asthenozoospermic men; O, oligozoospermic men; OA, oligoasthenozoospermic men; OT, oligoteratozoospermic men; OAT, oligoasthenoteratozoospermic men;
N, healthy fertile men. Text in light blue highlights outcome for fertility treatment. Rows in italic highlight information on frozen-thawed semen samples. SD, standard
deviation of the mean; SEM, standard error of the mean.
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forms compared to controls. In addition, sperm freezing in
the presence of MI resulted in a significant increase in antiox-
idant activity (ZB-TAC-96A commercial kit), as well as a
decrease in lipid peroxidation (malondialdehyde production)
and DNA fragmentation assessed by TUNEL assay. No signifi-
cant changes were observed in ROS between both groups.
The study is well designed, and the succesfull outcome
encourages its use in abnormal semen samples.
In addition to the studies designed to assess the impact on
semen parameters in fresh and frozen-thawed human spermato-
zoa, the effect of in vitro sperm incubation with MI on male fer-
tility was addressed by some authors. Among them, Poverini
et al. (2014) reported a prospective study done with couples
counseled for IUI cycles using MI supplemented swim-up
media, revealing an increase in clinical pregnancy rate after
treatment. Another study presented in a 2016 meeting, described
the impact of MI addition in the sperm preparation medium on
sperm quality and pregnancy rates in IUI procedures (Park et al.,
2016). The prospective study comprised a cohort of patients
divided into two groups, MI and control. Samples were sub-
grouped in N, O, and OA cases, and density-gradient centrifuga-
tion was used to select motile spermatozoa. The study revealed a
trend toward higher pregnancy rates in A and OA patients with
semen samples treated with MI, although similar sperm parame-
ters were determined in cell suspensions regardless of
treatment.
To address the impact of sperm treatment with MI on in vitro
fertilization and embryo development in IVF-ICSI procedures,
Rubino et al. (2015) published a report of a prospective bicentric
randomized study to assess the impact of MI in fertilization out-
comes of microinjected oocytes. Semen samples were supple-
mented with MI or placebo, washed and then subjected to
swim-up with MI or placebo-supplemented medium; spermato-
zoa recovered after selection were used for ICSI. Fertilization
rate and embryonic development were registered. MI-treated
spermatozoa depicted a discrete significant increase in sperm
motility after swim-up. Moreover, a significant increase in fertil-
ization rate and the percentage of day 3 grade A embryos was
found in the MI group when compared to the control. However,
the percentage of expanded blastocysts was similar in both
groups, and no differences were found in implantation or preg-
nancy rates. This was the first report describing the positive
impact of MI supplementation in in vitro sperm selection on fer-
tilization rate and early embryo development after ICSI
procedures.
IN VIVO AND IN VITRO SEMEN SUPPLEMENTATION
WITH MYO-INOSITOL AND IMPACT ON SPERM
FERTILIZING POTENTIAL
In addition to the in vivo and in vitro protocols tested to assess
the impact of MI treatment on male infertility, in a 2017 report,
Korosi and collaborators described the effect of combining both
approaches on sperm performance in IVF-ICSI procedures (Kor-
osi et al., 2017). The prospective randomized controlled trial of
couples involved male partner treatment with MI. In addition,
semen samples from these patients provided for the ART proce-
dures were subjected to gradient centrifugation and swim-up
procedures for motile sperm selection, followed by incubation
with MI. Finally, the sperm suspension was subjected to a final
sperm selection by means of hyaluronan hydrogel binding
(PICSI dish). Couples with OAT male partners who did not
receive any in vivo and in vitro MI treatment served as control.
Patient treatment with MI was associated with a higher fertiliza-
tion rate and a higher percentage of good-quality embryos. Preg-
nancies were obtained only in the MI-treated group, indicating a
positive impact of the supplement. These findings are summa-
rized in Table 3.
CONCLUDING REMARKS/ PERSPECTIVES
This review work has presented an overview of MI identifica-
tion, natural dietary sources and absorption, biosynthesis and
concentrations in human tissues and body fluids. Moreover, it
has outlined information on MI functions in its free form as well
as through its derivatives (PI, PIP, GPI, IPG) and their impact in
health and disease, highlighting the relevance of this molecule in
numerous functions. The following sections described MI pres-
ence, biosynthesis and functions in the male genital tract and
spermatozoa, although the literature is scarce regarding the
underlying changes in reproductive tissues and sperm structure
and functions in association with MI deficiency. Based on the
background information about the molecule and its relevance in
several diseases, and the available formulations to treat patients
or use it in in vitro assays, its supplementation was initially
tested and reported in several clinical studies mainly from one
country, and has been extended to other countries as reflected
by recent reports. Studies evaluated the impact of in vivo MI
treatment on some hormones, as well as in vivo and in vitro sup-
plementation on sperm parameters from fresh and frozen-
thawed semen. Other studies have assessed the impact of MI
treatment on natural and assisted male fertility. In summary,
several studies have reported the beneficial use of different
Table 3 In vivo and in vitro supplementation with MI and impact in male fertility





35 MI-treated group: 22; control:
13 couples with OAT male
partners who did not receive
any in vivo and in vitro MI
treatment
Male partner treatment with a MI based
supplement (Folandrol, Exeltis, Hungary; a
formula equivalent to Andrositol described by
Montanino Oliva et al in 2016) for two months
ART semen sample subjected to gradient
centrifugation and swim-up procedures for
motile sperm selection, followed by incubation
for 2 h with 2 mg/mL Ins (Andrositol-LAB
(Lo.Li. Pharma, Rome, Italy)
The sperm suspension was subjected to a final
sperm selection by means of hyaluronan
hydrogel binding (PICSI dish)
(mean  SD)
Fertilization rate (%):
MI = 84.8 (134/158),
control = 60.5 (66/109)
(p < 0.001)
Day 3, good-quality embryos (%):
MI = 54.7, control = 32 (p = 0.001).
Number of pregnancies:
MI-treated group = 11,
control group = 0
Korosi et al. (2017)
OAT, oligoasthenoteratozoospermic men. Text in light blue with outcome from fertility treatment is highlighted.
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formulations of MI on sperm motility and DNA damage. In any
case, several studies failed to include appropriate controls, and
almost no investigation has reported the underlying mecha-
nisms of action. The background information on its possible
impact on male reproductive tract organs and sperm functions
encourages further investigations to unravel MI roles in sperm
physiology and the underlying molecular mechanisms. More-
over, larger prospective randomized controlled multicenter stud-
ies will contribute to confirm the positive effect of MI
supplementation in male infertility management.
NOTESNotes
1 MI: myo-inositol. Inositol has also been proposed as the
accepted abbreviation for myo-inositol, both free and in chemi-
cal combination (http://www.sbcs.qmul.ac.uk/iupac/cyclitol/
myo.html).
2 Alternative names: myo-inositol 1-phosphate synthase, short
name MI-1-P synthase; MIP synthase, short name hIPS; myo-
inositol 1-phosphate synthase A1, short name hINO1.
3 Alternative name: sodium/myo-inositol transporter 1, SMIT1.
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